|
Report Date : |
30.03.2013 |
IDENTIFICATION DETAILS
|
Name : |
BIOSPACIFIC INC. |
|
|
|
|
Registered Office : |
5980 Horton Street, Ste 360, Emeryville, CA 94608 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
1989 |
|
|
|
|
Legal Form : |
Corporation – Profit |
|
|
|
|
Line of Business : |
Manufactures, and supplies antibodies and antigens to develop diagnostic
assays for the commercial diagnostic industry in the United States. |
|
|
|
|
No. of Employees : |
10 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
Usually correct |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
United States - ECONOMIC OVERVIEW
The US has the largest and most technologically powerful economy in the world, with a per capita GDP of $48,100. In this market-oriented economy, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, they face higher barriers to enter their rivals' home markets than foreign firms face entering US markets. US firms are at or near the forefront in technological advances, especially in computers and in medical, aerospace, and military equipment; their advantage has narrowed since the end of World War II. The onrush of technology largely explains the gradual development of a "two-tier labor market" in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income. Imported oil accounts for nearly 55% of US consumption. Oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices increased another 50% between 2006 and 2008. In 2008, soaring oil prices threatened inflation and caused a deterioration in the US merchandise trade deficit, which peaked at $840 billion. In 2009, with the global recession deepening, oil prices dropped 40% and the US trade deficit shrank, as US domestic demand declined, but in 2011 the trade deficit ramped back up to $803 billion, as oil prices climbed once more. The global economic downturn, the sub-prime mortgage crisis, investment bank failures, falling home prices, and tight credit pushed the United States into a recession by mid-2008. GDP contracted until the third quarter of 2009, making this the deepest and longest downturn since the Great Depression. To help stabilize financial markets, in October 2008 the US Congress established a $700 billion Troubled Asset Relief Program (TARP). The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009 the US Congress passed and President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP; total government revenues from taxes and other sources are lower, as a percentage of GDP, than that of most other developed countries. The wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the US budget deficit and public debt - through 2011, the direct costs of the wars totaled nearly $900 billion, according to US government figures. In March 2010, President OBAMA signed into law the Patient Protection and Affordable Care Act, a health insurance reform bill that will extend coverage to an additional 32 million American citizens by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on health care - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010. In July 2010, the president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight. Long-term problems include inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, sizable current account and budget deficits - including significant budget shortages for state governments - energy shortages, and stagnation of wages for lower-income families.
|
Source
: CIA |
BIOSPACIFIC INC.
Address: 5980 Horton Street, Ste 360, Emeryville, CA 94608 - USA
Telephone: +1 510-652-6155
Fax: +1 510-652-4531
Website: www.biospacific.com
Corporate ID#: 1414394-5
State: Minnesota
Judicial form: Corporation – Profit
Date incorporated: 06-24-2005
Date founded: 1989
Stock: 1,000
shares common
Value: No
par value
Name of
manager: Gregory MELSEN
Business:
BiosPacific, Inc. develops, manufactures, and supplies antibodies and
antigens to develop diagnostic assays for the commercial diagnostic industry in
the United States.
The company offers products in the areas of cancer, cardiac markers,
drugs, endocrine/thyroid, human serum proteins, infectious diseases, steroids,
and stripped serums. Its products include monoclonal antibodies, affinity
purified polyclonal antibodies, purified proteins for immunoassay development,
and sample preparation resins. The company also engages in the distribution of
monoclonal antibodies. It serves immunodiagnostic kit manufacturers.
The company was founded in 1989 and is based in Emeryville, California.
As of July 6, 2005, BiosPacific, Inc. operates as a subsidiary of
Research And Diagnostic Systems, Inc.
No name of foreign suppliers available.
EIN: 94-3079620
Staff: 10
Operations & branches:
At the headquarters, we
find the corporate office and laboratory, on lease.
Shareholders:
RESEARCH AND DIAGNOSTIC SYSTEMS, INC.
614 McKinley Place NE
Minneapolis, MN 55413
USA
which is a wholly owned subsidiary of:
TECHNE CORP.
614 McKinley Place NE
Minneapolis, MN 55413
TECHNE Corporation develops, manufactures, and sells biotechnology
research and diagnostic products, and hematology calibrators and controls
worldwide. The company’s Biotechnology segment offers proteins, such as
cytokines, and enzyme substrates and inhibitors; antibodies, including
polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits
for the detection of human and animal proteins, and immunoassays that allow
researchers to quantify a specific analyte in a biological fluids sample;
clinical diagnostic immunoassay kits consisting of erythropoietin, transferrin
receptor, and beta2-microglobulin immunoassays for use as in vitro diagnostic
devices; flow cytometry products, such as fluorochrome labeled antibodies and
kits; intracellular cell signaling products, including antibodies,
phospho-specific antibodies, antibody arrays, active caspases, kinases,
phosphatases, and enzyme-linked
immunosorbant assays to measure the activity of apoptotic and signaling
molecules; and natural and synthetic chemical compounds for use as agonists,
antagonists, and inhibitors of various biological functions by investigators.
Its Hematology segment provides a range of hematology controls and
calibrators for impedance and laser type cell counters; and hematology control
products for use as proficiency testing tools by laboratory certifying
authorities.
The company was founded in 1976 and is headquartered in Minneapolis,
Minnesota.
The Company is listed with the Nasdaq under symbol TECH.
Sales 06-30-2012 (12 months): USD 314,600,000=
Net profit: USD
112,300,000)
Management:
Gregory MELSEN is the
interim CEO, after the retirement of Thomas OLAND.
He is also the CFO
As far as we know, he is interim CEO and CFO of the group.
Subsidiaries
And partnership: None
In United States, privately
held corporations are not required to publish any financials.
On a direct call, a
financial assistant controlled the present report but deferred any financials.
We sent a fax but no answer
received.
However, all financials are
consolidated with the parent company.
Other sources gave sales
for the Company up to USD 850,000=
Banks: Wells Fargo Bank
...
Legal filings & complaints:
As of today date, there is no legal filing pending with the Courts.
Secured debts summary (UCC):
None